CAS: 60811-17-8; 5-Bromo-2-Chloroaniline

上下游产品

4-bromo-1-chloro-2-nitrobenzene chloroform N-trichloro-anilide)acetic acid-(2,4,N-trichloro-anilide) m-Bromoaniline 2-bromo-5-chloro-[1,4]benzoquinone 5-bromo-2-chlorophenol N-(5-bromo-2-chloro-phenyl)-acetamide 2-chloro-5-bromofluorobenzene

5-溴-2-氯硝基苯置于镍体系中,用 甲醇 作为反应溶剂,化学反应生成 2-氯-5-溴苯胺
参考文献:Thiazolidine Derivatives
标题:Thiazolidine Derivatives
摘要:本发明涉及在4位具有羟基和3'-磺酰氨基-苯基取代基,在2位具有亚氨基,在1位具有脂肪族或环脂肪族取代基的噻唑烷衍生物.所述噻唑烷具有利尿活性.本发明还涉及制造所述化合物的方法.

专利信息

专利号:US-12006337-B2
优先权日:2018-05-30
标题:Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
发明人：HOLTZMAN MICHAEL J; ROMERO ARTHUR G; GEROVAC BENJAMIN J; HAN ZHENFU; KEELER SHAMUS P; WU KANGYUN; ZHANG YONG
权利人:WASHINGTON UNIVERSITY ST LOUIS
摘要:Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.

专利号:US-12384788-B2
优先权日:2019-09-13
标 题 :1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease
发明人：KOESTLER ROLAND; TASSEL JEAN; THORMANN MICHAEL; YEHIA NASSER; TREML ANDREAS; ALMSTETTER MICHAEL
权利人:ORIGENIS GMBH
摘要:The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for treating diseases, such as autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 40 to 146; examples 1 to 63; compounds 1 to 248; tables 1 to 3). Preferred compounds are e.g. 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds. An exemplary compound is e.g. 5-(2,6-difluorophenyl)-8-methoxy-1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine (example 49). (Formula (II):